Bank of America
FATE icon

Bank of America’s Fate Therapeutics FATE Stock Holding History

Bank of America’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Buy
188,564
+37,457
+25% +$45.6K ﹤0.01% 5302
2025
Q4 		$148K Buy
151,107
+4,554
+3% +$5.47K ﹤0.01% 5474
2025
Q3 		$185K Buy
146,553
+24,423
+20% +$26.3K ﹤0.01% 6316
2025
Q2 		$137K Sell
122,130
-266,313
-69% -$310K ﹤0.01% 6357
2025
Q1 		$307K Buy
388,443
+84,314
+28% +$103K ﹤0.01% 5929
2024
Q4 		$502K Sell
304,129
-550,066
-64% -$1.39M ﹤0.01% 5531
2024
Q3 		$2.99M Sell
854,195
-1,131,537
-57% -$4.4M ﹤0.01% 4214
2024
Q2 		$6.51M Buy
1,985,732
+65,956
+3% +$289K ﹤0.01% 3370
2024
Q1 		$14.1M Buy
1,919,776
+1,312,772
+216% +$8.13M ﹤0.01% 2627
2023
Q4 		$2.27M Buy
607,004
+414,932
+216% +$979K ﹤0.01% 4284
2023
Q3 		$407K Sell
192,072
-1,029,836
-84% -$3.41M ﹤0.01% 5451
2023
Q2 		$5.82M Sell
1,221,908
-932,621
-43% -$5.15M ﹤0.01% 3255
2023
Q1 		$12.3M Buy
2,154,529
+1,676,652
+351% +$10.1M ﹤0.01% 2616
2022
Q4 		$4.82M Buy
477,877
+142,932
+43% +$2.68M ﹤0.01% 3421
2022
Q3 		$7.51M Buy
334,945
+16,606
+5% +$480K ﹤0.01% 2910
2022
Q2 		$7.89M Sell
318,339
-5,772
-2% -$159K ﹤0.01% 2927
2022
Q1 		$12.6M Sell
324,111
-59,086
-15% -$2.29M ﹤0.01% 2639
2021
Q4 		$22.4M Buy
383,197
+142,026
+59% +$8.05M ﹤0.01% 2112
2021
Q3 		$14.3M Sell
241,171
-23,921
-9% -$1.88M ﹤0.01% 2490
2021
Q2 		$23M Buy
265,092
+44,646
+20% +$3.6M ﹤0.01% 2012
2021
Q1 		$18.2M Buy
220,446
+65,159
+42% +$6.24M ﹤0.01% 2119
2020
Q4 		$14.1M Buy
155,287
+58,870
+61% +$3.66M ﹤0.01% 2207
2020
Q3 		$3.85M Sell
96,417
-26,201
-21% -$915K ﹤0.01% 3147
2020
Q2 		$4.21M Sell
122,618
-19,405
-14% -$578K ﹤0.01% 2990
2020
Q1 		$3.15M Buy
142,023
+22,738
+19% +$575K ﹤0.01% 3109
2019
Q4 		$2.33M Sell
119,285
-6,324
-5% -$100K ﹤0.01% 3899
2019
Q3 		$1.95M Sell
125,609
-12,809
-9% -$246K ﹤0.01% 4077
2019
Q2 		$2.81M Buy
138,418
+17,464
+14% +$315K ﹤0.01% 3754
2019
Q1 		$2.13M Buy
120,954
+76,029
+169% +$1.2M ﹤0.01% 3937
2018
Q4 		$577K Buy
44,925
+17,598
+64% +$245K ﹤0.01% 4834
2018
Q3 		$445K Sell
27,327
-8,584
-24% -$102K ﹤0.01% 5034
2018
Q2 		$407K Buy
35,911
+25,511
+245% +$281K ﹤0.01% 5015
2018
Q1 		$101K Buy
10,400
+4,387
+73% +$42K ﹤0.01% 5736
2017
Q4 		$36K Buy
6,013
+3,845
+177% +$17.2K ﹤0.01% 6203
2017
Q3 		$9K Buy
+2,168
New +$7.37K ﹤0.01% 6576
2016
Q3 		– Sell
-28,320
Closed -$48K – 7179
2016
Q2 		$48K Buy
28,320
+92
+0.3% +$167 ﹤0.01% 5848
2016
Q1 		$51K Buy
28,228
+15,348
+119% +$31.6K ﹤0.01% 5783
2015
Q4 		$43K Buy
+12,880
New +$54.1K ﹤0.01% 6105
2014
Q1 		– Sell
-1,035
Closed -$6K – 7877
2013
Q4 		$6K Buy
+1,035
New +$6.52K ﹤0.01% 7429

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's FATE Position: Q1 2026 in Review

Bank of America increased its Fate Therapeutics (FATE) stake by 25% in Q1 2026, buying an estimated $45.6K and bringing the position to 188,564 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #5302.

Bank of America first reported a position in FATE in Q4 2013 and has held it in 39 quarters since. The position peaked at $23M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Bank of America held 188,564 shares of Fate Therapeutics worth $226K as of Q1 2026.
  • Bank of America bought 37,457 Fate Therapeutics shares in Q1 2026, an estimated $45.6K.
  • Fate Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5302 holding.
  • Bank of America first reported a position in Fate Therapeutics in Q4 2013 and has held it in 39 quarters since.
  • Bank of America's Fate Therapeutics position peaked at $23M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.